We are live on ! Find out more
BLPH

Bellerophon Therapeutics, Inc.
BLPH

Delisted

BLPH was delisted on the 13th of October, 2023.

Back to rankings

17 hedge funds and large institutions have $16.3M invested in Bellerophon Therapeutics, Inc. in 2016 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

21% more funds holding

Funds holding: 14 → 17 (+3)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

17% less capital invested

Capital invested by funds: $19.6M → $16.3M (-$3.29M)

Holders
17
Holders Change
+3
Holders Change %
+21.43%
% of All Funds
0.45%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
2
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$78.6K
2
Creative Planning
Creative Planning
Kansas
+$31.4K
3
GA
Geneva Advisors
Illinois
+$30.9K
4
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$11K
5
TRCT
Tower Research Capital (TRC)
New York
+$1.82K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$84.3K
2
ARTA
A.R.T. Advisors
New York
-$47K
3
BFA
BlackRock Fund Advisors
California
-$2.22K
Name Holding Trade Value Shares
Change 		Change in
Stake
NMVA
1
New Mountain Vantage Advisers
New York
$12M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$3.12M -$84.3K -2,273 -3%
Alyeska Investment Group
3
Alyeska Investment Group
Illinois
$354K +$11K +297 +3%
BCM
4
Bridgeway Capital Management
Texas
$246K – – –
Vanguard Group
5
Vanguard Group
Pennsylvania
$215K – – –
LPL Financial
6
LPL Financial
California
$131K – – –
Jacobs Levy Equity Management
7
Jacobs Levy Equity Management
New Jersey
$78K +$78.6K +2,119 New
BIT
8
BlackRock Institutional Trust
California
$70K – – –
GA
9
Geneva Advisors
Illinois
$31K +$30.9K +833 New
Creative Planning
10
Creative Planning
Kansas
$31K +$31.4K +847 New
BFA
11
BlackRock Fund Advisors
California
$23K -$2.22K -60 -9%
Bank of America
12
Bank of America
North Carolina
$3K – – –
UBS Group
13
UBS Group
Switzerland
$3K +$667 +18 +29%
BIM
14
BlackRock Investment Management
Delaware
$2K – – –
Walleye Trading
15
Walleye Trading
New York
$2K +$1.74K +47 New
TRCT
16
Tower Research Capital (TRC)
New York
$2K +$1.82K +49 New
Morgan Stanley
17
Morgan Stanley
New York
$1K – – –
ARTA
18
A.R.T. Advisors
New York
– -$47K -1,061 Closed

BLPH Hedge Fund Activity: Q1 2016 in Review

17 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Bellerophon Therapeutics, Inc. (BLPH) for Q1 2016, worth a combined $16.3M — down 17% from $19.6M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new BLPH positions and 2 closed out — a net gain of 3 holders — while 2 added to existing stakes and 2 trimmed.

The largest buyer was Jacobs Levy Equity Management, opening a new position worth an estimated $78.6K. The largest seller was Fidelity Investments, cutting an estimated $84.3K.

  • 17 institutional investors held Bellerophon Therapeutics, Inc. (BLPH) as of Q1 2016, up from 14 in Q4 2015.
  • Funds reported $16.3M of Bellerophon Therapeutics, Inc. stock for Q1 2016, down 17% quarter-over-quarter.
  • 5 funds opened new Bellerophon Therapeutics, Inc. positions in Q1 2016 and 2 closed out, a net change of +3 holders.
  • The largest Bellerophon Therapeutics, Inc. buyer in Q1 2016 was Jacobs Levy Equity Management, an estimated $78.6K added.
  • The largest Bellerophon Therapeutics, Inc. seller in Q1 2016 was Fidelity Investments, an estimated $84.3K sold.

Based on aggregated 13F filings for Q1 2016.